Business Context and Reporting Period
Company: Protalix Biotherapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Stage: Development stage biopharmaceutical company.
Core Focus: Development of recombinant therapeutic proteins using the proprietary ProCellEx plant cell-based expression system. The lead candidate is prGCD for the treatment of Gaucher disease, currently in a Phase III clinical trial.
Key Financial Metrics
| Metric (in thousands) | 9 Months Ended Sep 30, 2008 | 9 Months Ended Sep 30, 2007 | 3 Months Ended Sep 30, 2008 |
|---|---|---|---|
| Revenues | $830 | $0 | $0 |
| Net Loss | $(15,838) | $(17,350) | $(6,496) |
| Net Loss Per Share (Basic/Diluted) | $(0.21) | $(0.27) | $(0.09) |
| Cash and Cash Equivalents (Sep 30, 2008) | $46,045 | $20,440 (Sep 30, 2007) | N/A |
| Accumulated Deficit (Sep 30, 2008) | $(58,831) | $(42,993) (Dec 31, 2007) | N/A |
| Net Cash Used in Operating Activities | $(13,776) | $(6,997) | N/A |
| Net Cash Used in Investing Activities | $(2,941) | $(1,137) | N/A |
Debt and Liquidity: The company reported no long-term debt on the balance sheet. Total liabilities were $5.4 million, primarily consisting of current accounts payable and accruals ($4.4 million) and liabilities for employee rights upon retirement ($1.0 million). Management estimates current cash resources are sufficient to fund operations for approximately the next 24 months.
Material Changes vs. Prior Period
- Revenue: Generated $830,000 in revenue for the nine months ended September 30, 2008, compared to no revenue in the same period in 2007. This was primarily from research and development services.
- Net Loss: Net loss decreased by approximately 9% to $15.8 million for the nine-month period, compared to $17.4 million in the prior year. The reduction was driven by a significant decrease in share-based compensation expenses.
- Research & Development (R&D): R&D expenses increased by 66% to $15.8 million (net of grants) for the nine months ended September 30, 2008, compared to $9.5 million in 2007. This increase is attributed to the Phase III clinical trial of prGCD, higher salaries, and material costs. Grants from the Israeli Ministry of Industry offset expenses by $3.2 million.
- General & Administrative (G&A): G&A expenses decreased by 49% to $5.3 million for the nine-month period, compared to $10.5 million in 2007. This was primarily due to a $6.5 million reduction in share-based compensation resulting from a decrease in the fair value of common stock underlying certain options.
- Financial Income: Net financial income increased to $2.0 million for the nine-month period, up from $1.2 million in 2007, due to higher interest income on cash balances and currency exchange effects.
Guidance, Outlook, and Risks
Outlook and Guidance:
- Management expects to continue incurring operating losses for the foreseeable future as R&D expenses increase with advanced clinical trials.
- The company plans to file an Investigational New Drug (IND) application for at least one additional product by the first half of 2009.
- Cash resources are projected to sustain operations for approximately 24 months. Additional financing will be required for commercialization and further development.
Risks and Contingencies:
- Capital Requirements: No product revenues exist; the company relies on equity offerings, debt, or grants. Failure to secure funding could force delays or reductions in R&D.
- Clinical Trial Risks: Phase III trials for prGCD are expensive and time-consuming. Failure, delays, or safety issues could materially adversely affect the business.
- Regulatory Approval: Success depends on FDA and foreign regulatory approvals, which are uncertain.
- Stock Liquidity: Trading of common stock is limited. Lock-up agreements for former shareholders expire on January 1, 2009, potentially increasing supply and impacting stock price.
- Currency Risk: Approximately 35% of costs are incurred in New Israeli Shekels (NIS). Fluctuations in the USD/NIS exchange rate impact operating costs.
Investor Verification Checklist
- Cash Runway: Verify the 24-month liquidity estimate against current burn rates and potential unexpected capital expenditures (e.g., new manufacturing facility).
- Phase III Trial Status: Confirm patient enrollment rates and interim data for the prGCD Phase III trial and the extension study initiated in Q3 2008.
- Share-Based Compensation Volatility: Monitor the impact of stock price fluctuations on future G&A expenses, as seen in the significant variance between 2007 and 2008.
- Lock-Up Expirations: Assess the potential market impact of the January 1, 2009, expiration of lock-up agreements covering approximately 35.9 million shares.
- Grant Dependency: Evaluate the sustainability of R&D funding given the reliance on government grants (e.g., $3.2 million received in the first nine months of 2008).